<DOC>
	<DOCNO>NCT01681953</DOCNO>
	<brief_summary>The overall objective trial evaluate efficacy safety repeat Lamazym i.v . treatment , compare placebo , subject 5-35 year age alpha-Mannosidosis</brief_summary>
	<brief_title>A Placebo-Controlled Phase 3 Trial Repeated Lamazym Treatment Subjects With Alpha-Mannosidosis</brief_title>
	<detailed_description />
	<mesh_term>Mannosidase Deficiency Diseases</mesh_term>
	<mesh_term>alpha-Mannosidosis</mesh_term>
	<criteria>Subject subject legally authorize guardian ( ) must provide sign , inform consent prior perform trialrelated activity The subject his/her guardian ( ) must ability comply protocol The subject must confirm diagnosis alphaMannosidosis define alphaMannosidase activity &lt; 10 % normal activity ( historical data ) The subject must age time screen ≥ 5 year ≤ 35 year The subject must ability physically mentally cooperate test The subject must ECHO without abnormality , opinion Investigator , would preclude participation trial The subject diagnosis confirm alphaMannosidase activity &lt; 10 % normal activity The subject walk without support Presence know chromosomal abnormality syndrome affect psychomotor development , alphaMannosidosis History BMT Presence know clinically significant cardiovascular , hepatic , pulmonary , renal disease medical condition , opinion Investigator , would preclude participation trial Any medical condition serious intercurrent illness , extenuate circumstance , opinion Investigator , would preclude participation trial Pregnancy : Pregnant woman exclude . Before start treatment investigator woman childbearing potential perform pregnancy test decide whether need contraception Psychosis ; psychotic disease , also remission , exclusion criterion Planned major surgery , opinion Investigator , would preclude participation trial Participation interventional trial test IMP ( include Lamazym ) within last 3 month Adult patient , opinion Investigator , would unable give consent , legal protection guardianship Total IgE &gt; 800 IU/ml Known allergy IMP excipients ( SodiumPhosphate , Glycine , Mannitol )</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>